Pharmaceutical company Amneal Pharmaceuticals (NASDAQ: AMRX) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 9.9% year on year to $796.2 million. The company’s full-year revenue guidance of $3.15 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $0.30 per share was 30.3% above analysts’ consensus estimates.
Is now the time to buy Amneal? Find out by accessing our full research report, it’s free.
Amneal (AMRX) Q2 CY2026 Highlights:
- Revenue: $796.2 million vs analyst estimates of $768.2 million (9.9% year-on-year growth, 3.6% beat)
- Adjusted EPS: $0.30 vs analyst estimates of $0.23 (30.3% beat)
- Adjusted EBITDA: $206.5 million vs analyst estimates of $180.6 million (25.9% margin, 14.3% beat)
- The company lifted its revenue guidance for the full year to $3.15 billion at the midpoint from $3.1 billion, a 1.6% increase
- Management slightly raised its full-year Adjusted EPS guidance to $1.01 at the midpoint
- EBITDA guidance for the full year is $765 million at the midpoint, above analyst estimates of $748 million
- Operating Margin: 16.3%, in line with the same quarter last year
- Free Cash Flow was -$51.94 million, down from $60.99 million in the same quarter last year
- Market Capitalization: $6.09 billion
Company Overview
Founded in 2002 and growing into one of America's largest generic drug producers, Amneal Pharmaceuticals (NASDAQ: AMRX) develops, manufactures, and distributes generic medicines, specialty branded drugs, biosimilars, and injectable products for the U.S. healthcare market.
Revenue Growth
Reviewing a company’s long-term sales performance reveals insights into its quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Over the last five years, Amneal grew its sales at a decent 8.7% compounded annual growth rate. Its growth was slightly above the average healthcare company and shows its offerings resonate with customers.
Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Amneal’s annualized revenue growth of 9.5% over the last two years aligns with its five-year trend, suggesting its demand was stable. 
This quarter, Amneal reported year-on-year revenue growth of 9.9%, and its $796.2 million of revenue exceeded Wall Street’s estimates by 3.6%.
Looking ahead, sell-side analysts expect revenue to grow 2.7% over the next 12 months, a deceleration versus the last two years. This projection is underwhelming and indicates its products and services will face some demand challenges.
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.
Adjusted Operating Margin
Amneal has been an efficient company over the last five years. It was one of the more profitable businesses in the healthcare sector, boasting an average adjusted operating margin of 20.2%.
Looking at the trend in its profitability, Amneal’s adjusted operating margin rose by 1.2 percentage points over the last five years, as its sales growth gave it operating leverage.
This quarter, Amneal generated an adjusted operating margin profit margin of 17.6%, down 5.6 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue.
Earnings Per Share
We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.
Amneal’s EPS grew at an unimpressive 4.8% compounded annual growth rate over the last five years, lower than its 8.7% annualized revenue growth. However, its adjusted operating margin actually improved during this time, telling us that non-fundamental factors such as interest expenses and taxes affected its ultimate earnings.
We can take a deeper look into Amneal’s earnings to better understand the drivers of its performance. A five-year view shows Amneal has diluted its shareholders, growing its share count by 116%. This dilution overshadowed its increased operational efficiency and has led to lower per share earnings. Taxes and interest expenses can also affect EPS but don’t tell us as much about a company’s fundamentals. 
In Q2, Amneal reported adjusted EPS of $0.30, up from $0.25 in the same quarter last year. This print easily cleared analysts’ estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects Amneal’s full-year EPS to grow 5.2% from $0.95 to $1.00.
Key Takeaways from Amneal’s Q2 Results
It was good to see Amneal beat analysts’ EPS expectations this quarter. We were also glad its revenue outperformed Wall Street’s estimates. Zooming out, we think this quarter featured some important positives. The stock traded up 15.9% to $22.13 immediately after reporting.
Amneal put up rock-solid earnings, but one quarter doesn’t necessarily make the stock a buy. Let’s see if this is a good investment. We think that the latest quarter is only one piece of the longer-term business quality puzzle. Quality, when combined with valuation, can help determine if the stock is a buy. We cover that in our actionable full research report which you can read here (it’s free).
